# Intranasal Oxytocin for Infants With Prader-Willi Syndrome

> **NCT03245762** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Florida** · enrollment: 15 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** Oxytocin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03245762
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-01-04
- **Final completion:** 2018-01-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245762, "Intranasal Oxytocin for Infants With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03245762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*